HSPB8

Across TCGA pan-cancer cohorts, HSPB8 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated HSPB8 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher HSPB8 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated HSPB8 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where HSPB8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	II,III,IV	0.868	0.617	<.001	62	view →
CCRCC	DFS	Tertile	All	0.594	0.883	.013	11	view →
LSCC	DFS	Quartile	All	0.931	0.719	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

HSPB8–PDAC (DFS)

Open the PDAC breakdown →